Shilpa Medicare Ltd gets Europe approval for Varenicline Tablets, 0.5mg and 1mg

Shilpa Medicare Limited, headquartered at Raichur, Karnataka, India, has received closure of Decentralized Procedure for Varenicline Tablets, 0.5 mg and 1 mg. Commercial supplies shall be started after the approval of National Procedure.

Varenicline is indicated for smoking cessation in adults. It is used for quitting smoking.

This product had sales of about 57 Million USD as of December 2021 prior to a decline in sales due to drug shortage due to post-production quality issues. This approval will enable Shilpa to make this quality medicine available to adults who intend to quit smoking and fill the drug shortage.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 431.85 as compared to the previous close of Rs. 437.35. The total number of shares traded during the day was 69092 in over 2415 trades.

The stock hit an intraday high of Rs. 446.35 and intraday low of 428.95. The net turnover during the day was Rs. 30293172.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Europe Approval VareniclineTablets